| Veröffentlichte Version Download ( PDF | 538kB) | Lizenz: Creative Commons Namensnennung 4.0 International |
Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source – a series of four cases
Hitzenbichler, Florian
, Mohr, Arno, Camboni, Daniele, Simon, Michaela, Salzberger, Bernd und Hanses, Frank
(2021)
Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source – a series of four cases.
Infection 49, S. 181-186.
Veröffentlichungsdatum dieses Volltextes: 04 Feb 2021 14:19
Artikel
DOI zum Zitieren dieses Dokuments: 10.5283/epub.44749
Zusammenfassung
We present four cases with Gram-positive bacteremia (pathogens: MRSAn = 1, Enterococcusspp.n = 3) due to an intravascular source (left ventricular assist device:n = 2, transfemoral aortic valve implantationn = 1, prosthetic aortic valve:n = 1) where no curative treatment was available. These patients received indefinite, chronic suppressive (palliative) therapy with dalbavancin (500 mg weekly or ...
We present four cases with Gram-positive bacteremia (pathogens: MRSAn = 1, Enterococcusspp.n = 3) due to an intravascular source (left ventricular assist device:n = 2, transfemoral aortic valve implantationn = 1, prosthetic aortic valve:n = 1) where no curative treatment was available. These patients received indefinite, chronic suppressive (palliative) therapy with dalbavancin (500 mg weekly or 1000 mg biweekly regimens). Outcomes and clinical characteristics are described; treatment was effective in suppression of bacteremia in all patients over several months (range: 1 to more than 12 months), we observed no relevant side effects.
Alternative Links zum Volltext
Beteiligte Einrichtungen
Details
| Dokumentenart | Artikel | ||||
| Titel eines Journals oder einer Zeitschrift | Infection | ||||
| Verlag: | SPRINGER HEIDELBERG | ||||
|---|---|---|---|---|---|
| Ort der Veröffentlichung: | HEIDELBERG | ||||
| Band: | 49 | ||||
| Seitenbereich: | S. 181-186 | ||||
| Datum | 2021 | ||||
| Institutionen | Medizin > Lehrstuhl für Herz-, Thorax- und herznahe Gefäßchirurgie Medizin > Lehrstuhl für Medizinische Mikrobiologie und Hygiene Medizin > Institut für Epidemiologie und Präventivmedizin | ||||
| Identifikationsnummer |
| ||||
| Stichwörter / Keywords | SKIN; Dalbavancin; Bacteremia; Intravascular infection; Suppressive therapy; LVAD; Endocarditis | ||||
| Dewey-Dezimal-Klassifikation | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin | ||||
| Status | Veröffentlicht | ||||
| Begutachtet | Ja, diese Version wurde begutachtet | ||||
| An der Universität Regensburg entstanden | Ja | ||||
| URN der UB Regensburg | urn:nbn:de:bvb:355-epub-447490 | ||||
| Dokumenten-ID | 44749 |
Downloadstatistik
Downloadstatistik